key: cord-282339-a1ln2v2p
authors: Pinto, Daniel; Schmitt, Fernando
title: The role of breast FNA during and post‐ COVID‐19 pandemic: a fast and safe alternative to needle core biopsy
date: 2020-07-23
journal: Cytopathology
DOI: 10.1111/cyt.12894
sha: 
doc_id: 282339
cord_uid: a1ln2v2p

The coronavirus disease 2019 (COVID‐19) has been very taxing to healthcare systems worldwide. As resources are diverted to treat COVID‐19, capacity for diagnostic and therapeutic procedures of other diseases is reduced, resulting in delays and waiting lists. This is particularly important in the context of oncology, namely breast cancer. All patients with suspicious breast lesions need pathological confirmation of malignancy in order to be treated; unfortunately, many of these procedures have been delayed. Nowadays these lesions are usually diagnosed using core needle biopsies (CNB). When compared to fine‐needle aspiration biopsies (FNAB), they are perceived to be more precise and provide better material for biomarker testing. However, FNABs are quicker to perform, less costly and minimally invasive, which would seem advantageous in the context of growing waiting lists. We would invite the reader to challenge their preconceptions of breast FNABs: not only have ancillary tests have been shown to be viable on both smears and cell blocks but, in 2019, the Yokohama System for Reporting Breast Fine‐Needle Aspiration Biopsy Cytopathology was developed and validated, enabling an accurate and reproducible categorization of breast lesions, significantly reducing the need for follow‐up CNBs. Thus, the major limitations of breast FNABs have been addressed. Furthermore, they are less invasive, leading to a lower risk of infection for personnel when standard biosafety procedures are followed. The right tool must be chosen for the right task. In the world of COVID‐19, FNABs may yet again prove a valuable and even essential diagnostic tool for symptomatic breast lesions.

The coronavirus disease 2019 has spread all over the world, affecting most countries to varying degrees. As of the 10 th of July 2020, there were more than 12 million people infected worldwide and over 500000 casualties. (1) The way the pandemic played out in certain countries, such as the first wave in Italy, have shown how taxing this virus is for healthcare systems and how dire the situation can become when they are overwhelmed. (2) This is true not only for those directly or indirectly affected by the viral infection. A lot of attention has been focused on the economical consequences of the pandemic and the measures taken to control it. (3) (4) (5) (6) However, a few reports have also focused on the consequences for those affected by other severe pathologies. (2, (7) (8) (9) (10) The center for disease control (CDC) data shows that excess deaths, defined as the difference between observed numbers of deaths and expected numbers, excluding those attributed to COVID-19, have increased in the United States during the pandemic when compared to previous years, particularly in heavily affected areas such as the state of New York. (11) This may, at least in part, be attributed to the many constraints COVID-19 places on health services, both public and private. Severe cases often require access to ventilators and wellequipped intensive care units (ICUs). (12) Given the insufficient capacities in many countries and hospitals, units previously used for surgical and diagnostic procedures were converted to impromptu COVID-19 units. Health care personnel were diverted to these units, replacing their usual duties with COVID-19 patient treatment and triage. (13) The consequence is a reduced capacity for diagnostic and therapeutic procedures of unrelated pathologies. (2, (7) (8) (9) (10) This capacity was further decreased by the need to adapt procedures and provide adequate personal protection equipment (PPE) to healthcare professionals, since these patients may be harboring the disease and be contagious while remaining asymptomatic. (13) Furthermore, patients themselves may be avoiding looking for healthcare even when in need, for fear of contracting COVID-19 infection. (14) Data shows that this will invariably result in delays and increased waiting lists for diagnostic and therapeutic procedures of vital importance, which will be felt for years to come. (15, 16) Accepted Article

In the context of breast cancer, some of the patients affected by these delays were those with suspicious breast lesions detected clinically or through imaging studies. To recover from this situation, and reduce the increase in mortality and morbidity, innovative and unconventional strategies will necessarily have to emerge. All patients with suspicious lesions need pathological confirmation of malignancy in order to be treated, and diagnostic procedures have been deemed high priority by several international organizations. (17-19) As already established, many of these diagnostic procedures have been delayed, resulting in procedure backlogs. Furthermore, given that recommendations have been issued to suspend imagiological screening exams of the breast, these backlogs are bound to increase as the pandemic is controlled and procedures resumed. (20) Current practice guidelines recommend that the diagnosis of suspicious breast lesions classified radiologically as BIRADS 4 and 5 should be made using core needle biopsies (CNB). (21, 22 ) When compared to fine-needle aspiration biopsies (FNAB), CNBs have some advantages, such as enabling the assessment of suspicious microcalcifications detected by mammography, distinguishing in situ from invasive lesions and providing material for performing theranostic biomarkers, enabling personalized therapy. (23) However, FNABs of breast lesions have a long history in western medicine, and their diagnostic value cannot be understated. When coupled with ultrasound and rapid on-site evaluation (ROSE), they have been shown to be successful in the diagnosis of both palpable and nonpalpable ultrasound detectable breast lesions. Whereas CNBs are expensive, complex procedures, with an increased risk of complications, FNABs are quick to perform, cost-effective and minimally invasive. (24, 25) In the context of the COVID-19 pandemic, these features seem advantageous. By resorting to FNABs, clinicians may be able to save time and resources, which may be very limited at this time.

But even if they are less expensive and quicker to perform, these advantages would be negated if a CNB is still needed to obtain adequate material for the confirmation of invasion or to enable ancillary testing. We would argue, however, that these problems can now, more than ever, be

This article is protected by copyright. All rights reserved 

One could also argue that, given the minimal invasive nature of the FNAB procedure, the risk of infection from a asymptomatic COVID-19 patient should be low, and even lower when compared to a CNB procedure which may involve more personnel and time to perform. However, biosafety hazards in cytology are not limited to the aspiration procedure itself, but also involve transport, preparation and processing of specimens such as airdried smears. Those issues have been raised in recent publications. (32, 34) For instance, cytopathologists may work in pairs, reducing the time spent on each patient. If possible, after the procedure itself, all sample processing should be performed under a level 2 biosafety hood. However, if this is unavailable or unpractical, FFP2 / N95 masks and face shields should be sufficient to adequately protect personnel. Smears can be fixed in ethanol to avoid the generation of aerosols and droplets from these samples downstream. The material obtained through the FNA procedure may also be placed in a liquid medium, such as ethanol, enabling cyto-centrifuge preparations, or formaldehyde, enabling the preparation of cellblocks. (32, 34) These may be prepared using one of the several methods described in the literature. (35) 

This article is protected by copyright. All rights reserved CONCLUSIONS COVID-19 is a novel virus which has taken the world by surprise, through its ease of transmissibility, asymptomatic spread and lethality. Health systems have been overburdened and struggled to cope, deferring elective diagnostic and therapeutic procedures. In the case of breast cancer, this has led to a backlog of patients which will only worsen as imaging and diagnostic activity is resumed. CNBs of the breast have so far been the gold-standard for the diagnoses of breast lesions, given their reliability, reproducibility and accuracy of diagnosis. FNABs, however, are more cost-effective and quicker to perform. Their perceived limitations, such as the lack of a definitive diagnosis and poor interobserver reproducibility have been addressed by the Yokohama system. Furthermore, they have been shown to be able to provide adequate material for ancillary testing.

Pathologists may no longer be used to these samples, but extraordinary times require extraordinary measures. Through the use of the Yokohama system, which has been shown to be reproducible, with good communication with clinicians and image correlation, we believe FNABs may be a valuable and even essential diagnostic tool for tumoral breast lesions in the world of COVID-19.

Wordlometer -COVID-19 CORONAVIRUS PANDEMIC

COVID-19 OUTBREAK IN NORTHERN ITALY: VIEWPOINT OF THE MILAN AREA SURGICAL COMMUNITY

Coronavirus: A visual guide to the economic impact. BBC News

Coronavirus: the economic impact | UNIDO

Covid-19's economic impact: €100 billion to keep people in jobs | News | European Parliament

Coronavirus' business impact: Evolving perspective | McKinsey

Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic

Accepted Article This article is protected by copyright. All rights reserved 8

Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI

Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic

The Untold Toll -The Pandemic's Effects on Patients without Covid-19

Excess Deaths Associated

COVID-19 Treatment Guidelines

Transforming ORs into ICUs

Unusual STEMI Complications Blamed on COVID-19 Hospital Avoidance | tctmd

Returning NHS waiting times to 18 weeks for routine treatment [Internet]. The Health Foundation

Modelling the impact of COVID-19 on elective waiting times

Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. The Breast

COVID-19 Guidelines for Triage of Breast Cancer Patients

American College of Surgeons

ESMO management and treatment adapted recommendations in the COVID-19 era: Breast cancer

Joint Statement on Breast Screening Exams During the COVID-19 Pandemic

Breast Cancer Screening and Diagnosis, Version 3

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †

Core needle biopsy versus fine needle aspiration biopsy in breast-A historical perspective and opportunities in the modern era

Use of the "triple test" for palpable breast lesions yields high diagnostic accuracy and cost savings

Accepted Article This article is protected by copyright. All rights reserved

Breast fine needle aspiration continues to be relevant in a large academic medical center: experience from Massachusetts General Hospital

Ancillary Tests in Breast Cytology: A Practical Guide

The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy

International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology: A Review of Predictive Values and Risks of Malignancy

The 2017 Bethesda System for Reporting Thyroid Cytopathology

American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid

The continuing role of breast fine-needle aspiration biopsy after the introduction of the IAC Yokohama Breast FNAB Reporting System: an audit of its diagnostic performance

The COVID-19 pandemic: implications for the cytology laboratory

Accepted Article This article is protected by copyright. All rights reserved

Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID-19) infection: Perspectives from Taiwan

Cytology in the time of coronavirus disease (covid-19): an Italian perspective

Cytopathology in focus. Cell blocks: Getting the most from the least invasive method

Accepted Article

The authors have no conflict of interest to declare.

This article is protected by copyright. All rights reserved